Shell Asset Management Co. lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 7.0% during the fourth quarter, HoldingsChannel reports. The firm owned 28,664 shares of the life sciences company’s stock after selling 2,150 shares during the period. Shell Asset Management Co.’s holdings in Illumina were worth $6,263,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in ILMN. Jennison Associates LLC increased its stake in shares of Illumina by 8.8% in the 4th quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock worth $964,114,000 after acquiring an additional 355,200 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Illumina by 371.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 212,160 shares of the life sciences company’s stock worth $46,355,000 after purchasing an additional 167,206 shares during the last quarter. American Century Companies Inc. increased its position in shares of Illumina by 27.4% during the 3rd quarter. American Century Companies Inc. now owns 605,149 shares of the life sciences company’s stock worth $120,546,000 after purchasing an additional 130,038 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Illumina by 41.2% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 290,458 shares of the life sciences company’s stock worth $57,859,000 after purchasing an additional 84,690 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in shares of Illumina by 6,244.3% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 82,603 shares of the life sciences company’s stock worth $16,455,000 after purchasing an additional 81,301 shares during the last quarter. Institutional investors own 91.12% of the company’s stock.
Shares of Illumina, Inc. (ILMN) opened at $229.20 on Monday. The firm has a market capitalization of $33,692.40, a P/E ratio of 57.16, a P/E/G ratio of 3.03 and a beta of 0.92. Illumina, Inc. has a 52 week low of $158.02 and a 52 week high of $248.97. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.55 and a current ratio of 3.99.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The company had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. During the same quarter in the previous year, the business earned $0.85 earnings per share. The firm’s revenue for the quarter was up 25.7% on a year-over-year basis. analysts forecast that Illumina, Inc. will post 4.59 EPS for the current year.
In other Illumina news, EVP Omead Ostadan sold 3,540 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.91, for a total value of $803,261.40. Following the completion of the sale, the executive vice president now owns 26,827 shares in the company, valued at $6,087,314.57. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $225.33, for a total value of $32,672.85. Following the completion of the sale, the senior vice president now owns 6,388 shares of the company’s stock, valued at approximately $1,439,408.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,440 shares of company stock valued at $25,318,904. 0.89% of the stock is owned by company insiders.
A number of analysts recently issued reports on ILMN shares. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $252.00 price objective for the company in a research report on Tuesday, December 5th. Bank of America lifted their target price on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. Deutsche Bank raised Illumina from a “hold” rating to a “buy” rating and dropped their target price for the company from $195.00 to $160.00 in a research report on Monday, October 23rd. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $269.00 target price on shares of Illumina in a research report on Tuesday, January 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $241.39.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/19/shell-asset-management-co-decreases-holdings-in-illumina-inc-ilmn.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.